

Medicare Advantage Part B Drug Update Bulletin

December 2024

New and revised policies are posted on the website of Aspire Health Plan.

Effective December 15, 2024, the prior authorization criteria for some Part B drugs have been added, listed in [Table 1](#) below. **This bulletin summarizes the upcoming change in prior authorization criteria required before administering this medication in a physician's office.**

Aspire Health Plan (AHP) requires prior authorization for a select group of injectable drugs that may be administered under the medical benefit in a physician's office or by home infusion. These reviews are intended to ensure consistent benefit adjudication as well as appropriate utilization in accordance with the AHP Pharmacy & Therapeutics Committee's evidence-based criteria for coverage.

Table: Part B (Physician-Administered Drugs) Products that have updated prior authorization and / or Step Therapy criteria.

Policy Name	Drugs / J-Codes Impacted	Summary of Change
Oncology Drugs and Oncology Biosimilars <i>(Revised Policy)</i>	Added: 82 drugs and 94 respective HCPCS codes (A codes and J-codes) Refer 'to Oncology Drugs and Oncology Biosimilars' Policy for a list of drugs and codes in the 'Applicable HCPCS' section.	This clinical policy has been updated to include more HCPCS codes that will require prior authorization, and step therapy will be required for select drugs beginning December 1, 2024. Refer to Part B Prior Authorization Drug List and Part B Step Therapy Updates
Reblozyl (luspatercept-aamt) <i>(New Policy)</i>	Added: J0896: Injection, luspatercept-aamt, 0.25 mg	The Reblozyl (luspatercept-aamt) Policy is a new clinical policy that will require prior authorization effective December 1, 2024. Policy is posted on AHP's website in the Medicare Part B Drug Coverage section.
Kisunla (donanemab-azbt) <i>(New Policy)</i>	Added: J0175: Injection, donanemab-azbt, 2 mg	Coverage requires prior authorization . Refer to AHP's Kisunla Clinical Policy.

Committee Approved August 27, 2024

